OR-ADVA
18.8.2021 09:02:14 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that Portland General Electric (PGE) is deploying Oscilloquartz PTP grandmaster clock technology as it upgrades to packet-based synchronization and protects its network against GNSS vulnerabilities and cyberattacks, while conforming to PNT Executive Order 13905. PGE, one of the largest power utilities in the Western United States, is using ADVA scalable timing solution to not only enable a smooth transition from legacy synchronization and ensure new levels of accuracy, reliability and resiliency but also to timestamp data and control grid substations at the edge. With multi-band GNSS receivers and AI-powered threat detection, ADVA’s assured PNT (aPNT) platform helps maintain resilient timing, even in challenging circumstances such as deliberate jamming and spoofing attacks. Easy to install and operate, the solution also provides multi-source backup, including PTP network timing and in-device holdover oscillators for when GNSS signals are unavailable or disrupted.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210818005033/en/
“Precise and resilient synchronization is increasingly vital in the power industry. By harnessing new time-sensitive applications and building smarter energy infrastructure, we can offer even more to customers across our region. ADVA’s Oscilloquartz technology will be a key tool as we continue to lead the way to a more sustainable and affordable energy future for our community,” said John Lozano, senior telecommunications engineer, PGE. “ADVA’s OSA 5420 Series supports our existing synchronization services while also enabling packet time distribution all the way to the edge of our network. With its GPS jamming and spoofing detection, it provides a robust yet cost-efficient defense against cyber threats. It also makes maintenance and configuration simple with an easy-to-operate web GUI and customizable database.”
PGE’s new timing infrastructure will distribute stable and accurate frequency, phase and time-of-day information between its power infrastructure data points, including PMUs, IEDs and substation LAN IEC 61850 communications, supporting rapid decision-making and automated assurance. The solution is built on the OSA 5410 and OSA 5420 Series of edgeSync+™ grandmaster clocks. It features multi-band, multi-constellation GNSS receivers and supports multiple PTP profiles, including substation power and core telecom backup sync, while also allowing conversion between them and supporting legacy interfaces. The products are part of ADVA’s new aPNT platform, integrating threat detection, multi-source backup and ADVA’s intelligent Ensemble Sync Director , as the new trusted standard for PNT service assurance, control and visibility.
“We’re proud that PGE is leveraging our synchronization technology and the support of our team as it makes the shift to next-generation timing. With its compact and environmentally friendly design, our technology will bring assured and protected synchronization to the edge of PGE’s network, enhancing efficiency and enabling it to take advantage of emerging smart grid applications,” commented John Scherzinger, SVP, sales, Americas, ADVA. “PGE’s highly resilient new solution will deliver the nanosecond accuracy and the levels of timing availability required by tomorrow’s power utilities. It features aPNT capabilities, our centralized GNSS monitoring and assurance tool for predictive maintenance, and our multi-band receivers with the power to compensate for ionospheric delay variations and protect against GNSS vulnerabilities.”
Further information on ADVA’s aPNT platform is available in this sync guide: https://adva.li/apnt-sync-guide .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210818005033/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
